HC Wainwright Has Pessimistic Outlook of MetaVia Q2 Earnings

MetaVia Inc. (NASDAQ:MTVA) – Analysts at HC Wainwright cut their Q2 2026 earnings estimates for shares of MetaVia in a research report issued on Monday, May 18th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.87) per share for the quarter, down from their previous estimate of ($0.85). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($2.72) per share. HC Wainwright also issued estimates for MetaVia’s Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($1.06) EPS, FY2026 earnings at ($3.69) EPS, FY2027 earnings at ($4.61) EPS, FY2028 earnings at ($2.43) EPS, FY2029 earnings at ($1.91) EPS and FY2030 earnings at ($1.58) EPS.

A number of other brokerages also recently issued reports on MTVA. Wall Street Zen raised shares of MetaVia from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a report on Friday, April 24th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $20.00.

MetaVia Stock Up 69.4%

Shares of NASDAQ MTVA opened at $1.88 on Wednesday. The firm’s 50-day moving average price is $1.38 and its 200-day moving average price is $4.38. The company has a market cap of $9.70 million, a PE ratio of -0.22 and a beta of 0.59. MetaVia has a 52-week low of $0.97 and a 52-week high of $19.03.

MetaVia (NASDAQ:MTVA) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.03).

Hedge Funds Weigh In On MetaVia

A hedge fund recently raised its stake in MetaVia stock. SG Americas Securities LLC lifted its holdings in MetaVia Inc. (NASDAQ:MTVA) by 44.2% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 60,386 shares of the company’s stock after purchasing an additional 18,506 shares during the period. SG Americas Securities LLC owned about 0.25% of MetaVia worth $57,000 at the end of the most recent reporting period. Institutional investors own 1.37% of the company’s stock.

Key Headlines Impacting MetaVia

Here are the key news stories impacting MetaVia this week:

• Positive Sentiment: MetaVia’s ADA 2026 acceptance gives investors a near-term catalyst tied to obesity and cardiometabolic data readouts, which can drive speculative interest in the stock. Article Title
• Neutral Sentiment: HC Wainwright reaffirmed its Buy rating and $20 price target on MetaVia, suggesting long-term optimism despite the stock’s volatility. Article Title
• Negative Sentiment: HC Wainwright lowered EPS estimates for multiple periods, including Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, FY2028, FY2029, and FY2030, reflecting a more cautious earnings outlook.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.